Analyzing Natural Glycosylated PEG-IL2v with Treg Bias for ALS & Autoimmune Diseases
Time: 11:00 am
day: Day 2 Treg Modulators Track AM
Details:
- Designing the best IL-2v for chronic inflammatory diseases
- CTM201 is the first long-acting PEG-IL2v without compromising its bioactivity
- Examining the PK/PD and safety profiles of CTM201 in ALS patients
